Viewing StudyNCT00585195

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 6:59 PM
Last Modification Date: 2024-10-26 @ 9:40 AM
Study NCT ID: NCT00585195
Status: COMPLETED
Last Update Posted: 2023-02-08
First Post: 2007-12-29
Brief Title: A Study Of Oral PF-02341066 A C-MetHepatocyte Growth Factor Tyrosine Kinase Inhibitor In Patients With Advanced Cancer
Sponsor: Pfizer
Organization: Pfizer
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Advanced Malignancies Except Leukemia
Non-Small Cell Lung Cancer ALK-positive
Non-Small Cell Lung Cancer c-Met Dependent
Non-Small Cell Lung Cancer ROS Marker Positive
Systemic Anaplastic Large-Cell Lymphoma
Keywords:
Name View
c-Met exon 14 alterations View
Crizotinib View
dose-finding View
drug-drug interaction View
ALK rearrangements View
c-Met mutations or amplifications View
c-Met dependent tumors View
ROS1 rearrangements View
c-Met exon 14 deletion View
c-Met exon 14 skipping View